Vision Restoration
The human eye is already built to repair itself. Vision Restoration is the effort to reawaken, amplify, guide, and complete that capacity — bringing back sight that has been lost, by leading with the body’s own regeneration. The retina’s light-sensing cells, the optic-nerve connection to the brain, and the eye’s own tissue can, in principle, be regrown and reconnected — without creating new harm.
The goal is not to accept lost vision as permanent. It is to bring sight back — to regenerate the retina’s light-sensing cells, regrow the optic-nerve connection to the brain, and rebuild the eye’s own tissue by reawakening the body’s natural power to repair itself. This capability is built around the body’s own regeneration first — with invasive procedures honestly labeled as research, never the finished model. Bringing a person’s sight back should never depend on wealth, geography, or luck. As we automate the global economy, we are driving the real cost of this restoration toward zero — so that it becomes something freely given to everyone, at the point of use.
Vote Michael Floyd for President 2028.
For most of history, vision loss was treated as a one-way door — once photoreceptors or the optic nerve died, sight was considered unrecoverable. That is changing. Nature already proves it is possible: fish and amphibians regrow damaged retinas and recover sight, and the same regenerative ability lies dormant in the human eye. The building blocks to switch it back on — reprogramming the retina’s own cells, regrowing the optic nerve, and rebuilding tissue from the body’s own stem cells — already exist, scattered across labs worldwide. The opportunity is to unify them into one restoration capability.
No person should be told that their blindness is permanent when the science to bring sight back is already emerging. No family should accept that a loved one will never see their face again. No one should lose the world when the body’s own power to repair the eye can be reawakened. Vision Restoration is about giving back independence, giving back opportunity, and giving back the moment of seeing a loved one’s face again — reconnecting people to the faces they love, the work they value, and the world they want to see again.
Restoring vision does not simply give back sight. It gives back independence, confidence, opportunity, and connection. It can let a person recognize the faces of the people they love again, return to the work they value, and watch a sunrise, a familiar street, or the colors of the world come back into view.
Millions of Americans live with vision loss once considered permanent. As regeneration becomes real, that loss becomes something we can begin to reverse — restoring people to their families, their jobs, and their communities, reducing disability and dependence, and returning human potential that was thought to be gone. Vision Restoration is built on a simple belief: no one should be told their sight is unrecoverable when the science to bring it back is within reach.
Unify currently fragmented capabilities into one closed-loop restoration system built on a simple reality: the human eye is already built to repair itself, and the goal is to reawaken, amplify, guide, and complete it. AI maps what is still alive and the safest path to bring it back; the retina’s own regeneration is reawakened; the optic-nerve connection is regrown; aged cells are reset to a younger functional state; function is restored without surgery as the brain re-learns to see; regenerative signals are delivered through harm-free, topical routes; and lost tissue is rebuilt from the body’s own cells — leading with the body’s own repair, while invasive approaches are honestly recognized as research rather than the intended end state. Under Michael Floyd’s Healthy standard, they are not the preferred model and qualify only when future versions become noninvasive, precisely controlled, durable, safe, and free of treatment-related harm. The purpose is simple: bring back sight that was lost, without creating new health problems.
One place for the whole picture: how each restoration capability works, the breakthrough that proves it is real, and the research and institutions behind it. AI supports human clinicians; it never replaces them.
These capabilities are not separate, competing cures — they are stages of one connected path, each handing off to the next, from the first map of the eye to restored, monitored sight:
The path above is the journey. The capabilities below are the science that makes it possible — the proven breakthroughs, and the people who achieved them. Some stages draw on several capabilities; some capabilities serve more than one stage.
Rescue the surviving cells Emerging · endogenous
Demonstrated components (today): between a healthy retinal cell and a dead one lies a window in which a stressed-but-living photoreceptor or retinal ganglion cell can be pulled back through the cell’s own survival machinery — neurotrophic support, anti-apoptotic signaling, and metabolic rescue. The retina makes its own survival factors, and stressed cells can reverse course if the stress is relieved in time.
The capability being built toward: reliably catching failing visual neurons inside that rescue window and restoring them with the eye’s own protective biology — preventing loss rather than replacing what is gone. When fully built, the aim is dependable rescue in patients; the rescue window and the survival signals are demonstrated in the lab, and well-targeted, durable delivery is the direction.
A stressed neuron is not necessarily a doomed one. Retinal cells run intrinsic survival pathways and even secrete factors that protect their neighbors; a failing cell can downshift into a reversible, dormant-like state and recover if survival signaling is restored before it commits to death.
The retina makes its own cell-survival factor. Thierry Léveillard and José-Alain Sahel at the Institut de la Vision (Sorbonne Université, Paris) identified rod-derived cone viability factor (RdCVF) in Nature Genetics (2004) — a protein secreted by rod photoreceptors that keeps neighboring cones alive by supporting their glucose metabolism. The body’s own protective signaling; harnessing it as a therapy is still in development.
Dying retinal ganglion cells have a reversible window. Wenting You, Theo Gorgels, and Chris Reutelingsperger at Maastricht University showed (2024) that rat retinal ganglion cells driven into the cell-death program could still recover normal form when the stressor was removed in time — direct evidence stressed cells are not immediately lost. A cell-level result defining the window, not yet an in-patient therapy.
Sustained survival support can preserve photoreceptors in people. Encapsulated-cell implants delivering ciliary neurotrophic factor (the NT-501 implant) were tested in early human trials for retinitis pigmentosa and geographic atrophy, showing safe long-term delivery and structural photoreceptor preservation on imaging. Honest boundary: this uses an implant and did not consistently improve vision — proof of the survival principle, with delivery still maturing.
Research & institutions: Thierry Léveillard and José-Alain Sahel (Institut de la Vision, Sorbonne Université; University of Pittsburgh), Wenting You, Theo Gorgels and Chris Reutelingsperger (Maastricht University), the National Eye Institute, the UCL Institute of Ophthalmology, the Wilmer Eye Institute at Johns Hopkins, and the broader retinal neuroprotection field.
Reawaken dormant function Emerging · behavioral
Demonstrated components (today): some visual cells and circuits are not dead but dormant — connections suppressed, signaling gated off rather than destroyed. The adult brain’s visual plasticity is held back by active molecular “brakes” that can be lifted, and adults with long-standing amblyopia have recovered vision once thought permanently lost — evidence that quiet-but-living visual machinery can be switched back on.
The capability being built toward: reawakening existing-but-silenced visual function — reopening adult plasticity and reactivating suppressed circuitry so dormant cells resume working, without replacing any cells. When fully built, the aim is reliable, on-demand reawakening; the brakes and the recovery are demonstrated, and dependable reactivation is the emerging direction.
Vision loss is not always cell loss. Developmental “critical periods” close as molecular brakes — extracellular-matrix and inhibitory-circuit changes — actively lock connections in place. Because the connections are suppressed rather than gone, lifting the brakes or driving the right activity can reopen plasticity and let silenced pathways carry signal again.
Adult plasticity is actively braked, not simply lost. Takao Hensch at Harvard University showed that visual-cortex plasticity closes because of developmentally up-regulated molecular brakes — including extracellular-matrix consolidation — rather than passive decline, and that lifting these brakes can reopen plasticity. Mechanistic, largely animal-model work establishing that dormant circuitry can be reawakened.
Adults with amblyopia recover vision once deemed unrecoverable. Dennis Levi at UC Berkeley, with Daphne Bavelier at the University of Rochester and Geneva, used perceptual learning and tailored visual training to improve acuity and even restore stereo depth in adults with long-standing “lazy eye” — purely through structured visual experience. A real, endogenous, behavioral reawakening in humans, though gains vary and it is not yet a standardized cure.
Functional silencing can precede irreversible loss. Studies of retinal ganglion cells in glaucoma describe a reversible, low-metabolism dysfunction — synapses retracted, excitability dialed down — that can recover if stressors are relieved. Honest boundary: device-based approaches like optogenetics also aim to reactivate retinal signaling, but those are engineered overrides, not the endogenous reawakening this capability centers on.
Research & institutions: Takao Hensch (Harvard University), Dennis Levi (UC Berkeley), Daphne Bavelier (University of Rochester; University of Geneva), Lamberto Maffei and the University of Pisa visual-plasticity tradition, the National Eye Institute, the UCL Institute of Ophthalmology, Maastricht University, and the broader visual-plasticity field.
Topical & noninvasive regenerative delivery Frontier
Demonstrated components (today): regeneration is most powerful when it can be received without creating new harm, and needle-free delivery is already real in places — regenerative biologics have reached the eye as eye drops (cenegermin/NGF, FDA 2018), and topical and mucus-penetrating nanoparticle carriers can carry signals deeper without injection.
The capability being built toward: delivering restorative signals through eye drops, topical biologics, penetrating nanoparticles, and other needle-free routes — so regeneration reaches people without injections, surgery, or added injury. The biology is only half the story; getting it in safely is the other half. When fully built, harm-free regeneration reaches everyone; the first noninvasive routes are real today, and replacing every injection is the direction.
Topical and eye-drop delivery of regenerative and neurotrophic signaling, sustained-release depots, nanoparticle and penetration-enhancing carriers, and noninvasive routes capable of carrying larger protein- and gene-based therapies to the front and — increasingly — the back of the eye. An active delivery-science direction, not yet a finished public solution.
Regenerative proteins can already be delivered as a drop. Alessandro Lambiase and colleagues developed recombinant human nerve-growth-factor eye drops (cenegermin, FDA-approved 2018) shown to regrow corneal nerves and heal the ocular surface — proof that a regenerative biologic can be delivered noninvasively, with no needle and no operation, and still rebuild living tissue. Researchers are now extending nanoparticle and sustained-release carriers to carry larger regenerative and gene-based payloads deeper into the eye, toward the retina, by the same harm-free routes.
Reaching deeper than drops were thought to go. Justin Hanes and Jung Soo Suk at the Johns Hopkins Center for Nanomedicine engineered mucus- and gel-penetrating nanoparticle carriers that move proteins and other large molecules past the ocular surface toward the back of the eye in animal models — challenging the long-held assumption that the retina can only be reached by injection.
Sustained release without repeat needles. Building on Robert Langer’s sustained-release polymer work at MIT, slow-release depots and refillable carriers are being engineered so a single noninvasive application can keep delivering a regenerative signal over weeks or months — reducing, and ultimately aiming to remove, the need for repeated injections into the eye.
Research & institutions: Robert Langer’s sustained-release research at the Massachusetts Institute of Technology, Alessandro Lambiase’s nerve-growth-factor eye-drop research, Justin Hanes and Jung Soo Suk at the Johns Hopkins Center for Nanomedicine, the Johns Hopkins Wilmer Eye Institute, Brown University ocular-delivery research, the National Eye Institute, University of California San Diego Shiley Eye Institute, University of Southern California, University of Illinois Chicago, University of Florida ophthalmic-delivery research, the ARVO ocular drug-delivery research community, military-funded ocular drug-delivery and regenerative-medicine research initiatives, and the broader ocular nanomedicine, topical biologics, and noninvasive retinal-delivery field.
Reawaken the retina’s own regeneration Demonstrated (animal) · endogenous
Demonstrated components (today): the supportive Müller glia already in the human retina are latent progenitors — in fish they naturally regenerate lost photoreceptors and neurons, and in mammals researchers have reprogrammed them toward new retinal neurons in the lab.
The capability being built toward: waking up that same latent ability in the human eye, so the retina regrows its own lost cells from the cells already there — no replacement retina needed. When fully built, the aim is endogenous retinal regeneration on demand; the Müller-glia reserve and its reprogramming are demonstrated in animals, and turning it on safely in people is the direction. The core of retinal regeneration.
Müller-glia reprogramming, proneural transcription factors, endogenous retinal stem-cell activation, and de-novo photoreceptor genesis from the retina’s own cells — shown in animals, not yet a finished human solution.
Nature already regenerates retinas. Pamela Raymond and Daniel Goldman at the University of Michigan showed that in zebrafish, after retinal injury the Müller glia re-enter the cell cycle, become progenitor cells, and replace lost retinal neurons — fully restoring vision. This is the biological proof retinal regeneration is possible, and the blueprint researchers are switching on in mammals.
Blind mice see after the retina regrows its own rods. Bo Chen’s team at the Icahn School of Medicine at Mount Sinai reprogrammed Müller glia into functional rod photoreceptors inside living mice — without injuring the retina first — using two-step gene activation (beta-catenin, then Otx2, Crx, and Nrl). The new rods wired into the visual pathway and restored vision in congenitally blind mice (Nature, 2018).
Adult retinal cells coaxed into new neurons. Thomas Reh’s lab at the University of Washington showed that switching on the proneural factor Ascl1 drives adult mouse Müller glia to regenerate functional retinal neurons — directly mimicking how fish regenerate their retinas (Jorstad et al., Nature, 2017).
Research & institutions: Bo Chen’s Ocular Stem Cell Program at the Icahn School of Medicine at Mount Sinai, Thomas Reh’s lab at the University of Washington, Daniel Goldman and Pamela Raymond’s zebrafish retinal-regeneration research at the University of Michigan, Rachel Wong’s retinal-circuit research at the University of Washington, Michael Dyer’s retinal-development and regeneration research at St. Jude Children’s Research Hospital, Seth Blackshaw’s retinal cell-identity and regeneration research at Johns Hopkins University, Constance Cepko’s retinal-development research at Harvard Medical School, Andy Fischer’s Müller-glia reprogramming research at the Ohio State University, Donald Zack’s lab at the Johns Hopkins Wilmer Eye Institute, the National Eye Institute Audacious Goals Initiative, and the broader Müller-glia retinal-regeneration field.
Regrow the optic-nerve connection Demonstrated (animal)
Demonstrated components (today): retinal ganglion cells carry a dormant growth program from development, and researchers have reactivated it in animals — switching the cells’ own regenerative pathways back on — so severed axons regrow long distances through the optic nerve.
The capability being built toward: rebuilding the wiring between eye and brain by reawakening that growth program so axons regrow and reconnect to their correct targets. When fully built, the aim is a fully reconnected eye-brain pathway; long-distance regrowth is demonstrated in animals, and correctly-targeted reconnection in people is the direction. Shared with optic-nerve regeneration.
Retinal-ganglion-cell axon regeneration, intrinsic growth-pathway reactivation, growth-factor signaling, and target reconnection — long-distance regrowth shown in animals, with functional recovery still partial.
The optic nerve regrown to the brain. Zhigang He’s lab at Boston Children’s Hospital and Harvard Medical School found that removing the brakes PTEN and SOCS3 reactivates retinal ganglion cells’ own growth program; combined with intraocular signaling, their axons regrew the full length of the optic nerve, reached brain targets, and restored simple visual responses (Park et al., Science, 2008).
Stacking the growth signals. Larry Benowitz and colleagues showed that combining the inflammation-derived factor oncomodulin with raised cAMP and removal of PTEN drives far stronger retinal-ganglion-cell axon regeneration than any single signal — establishing that regrowth can be amplified by combining the eye’s own growth cues.
Guiding axons back to the right targets. Follow-on work from these labs showed regrown axons can be steered along their original routes to the correct visual centers in the brain and restore measurable visual responses — addressing not just how far axons grow, but whether they reconnect correctly.
Research & institutions: Zhigang He’s lab at Boston Children’s Hospital and Harvard Medical School, Larry Benowitz’s optic-nerve regeneration research, Jeffrey Goldberg’s lab at Stanford University, Yang Hu’s optic-nerve regeneration research, Thomas Johnson’s vision-restoration research at Johns Hopkins University, the Louis J. Fox Center for Vision Restoration at Mass Eye and Ear, the National Eye Institute, the National Eye Institute Audacious Goals Initiative, the Department of Defense Vision Research Program, the Congressionally Directed Medical Research Programs (CDMRP) Vision Research Program, military traumatic-optic-neuropathy research initiatives, ARPA-H THEA, Stanford VISION, University of Pittsburgh Ophthalmology, Carnegie Mellon University, the Wyss Institute at Harvard University, Lions World Vision Institute, University of Colorado Anschutz Medical Campus, and the broader optic-nerve regeneration field.
Reset cells to a younger, functional state Frontier · animal
Demonstrated components (today): cells carry an epigenetic “age” — chemical marks on top of the DNA that drift with time and quietly switch off a cell’s ability to repair itself. Partial epigenetic reprogramming has rolled back that age in retinal neurons in animals, restoring lost function without changing cell identity or the DNA itself.
The capability being built toward: restoring youthful repair and regeneration to the eye’s own surviving cells by safely resetting their epigenetic age. When fully built, the aim is controlled rejuvenation of aged retinal cells in people; the rollback is demonstrated in animals, and doing it safely and noninvasively in humans is the frontier. A direction that uses the body’s own cells.
Partial epigenetic reprogramming, restoration of youthful gene-expression patterns, age-reversal of retinal ganglion cells, and reactivation of intrinsic repair. The approach uses a controlled, transient pulse of reprogramming factors — enough to reset the epigenetic clock and reawaken repair, while stopping well short of erasing what the cell is. Demonstrated in animals.
Vision loss reversed by resetting cellular age. David Sinclair’s lab at Harvard Medical School, with lead author Yuancheng Lu, delivered three reprogramming factors (Oct4, Sox2, Klf4) that reset the age of retinal ganglion cells, regenerated the optic nerve, and reversed vision loss in mouse models of glaucoma and aging — the first reversal of glaucoma-induced vision loss rather than merely slowing it (Nature, 2020). The reversal worked through the cell’s own DNA-demethylation system (the TET enzymes) rewinding age-related marks, and the recovered neurons kept their original identity — showing the reset restored function rather than overwriting the cell. The result has since become a foundation for the wider cellular-rejuvenation field.
Built on a Nobel-winning discovery. The reset uses reprogramming factors from Shinya Yamanaka’s Nobel Prize–winning finding that adult cells can be returned to a youthful, flexible state. Partial reprogramming applies just enough of that reset to restore function while deliberately stopping before the cell loses what it is.
A field racing to translate it safely. Because the eye is accessible and its cells are easy to measure, the retina has become one of the first proving grounds for turning partial reprogramming into a safe therapy, with multiple labs and companies now working to move it from animals toward people.
Research & institutions: David Sinclair’s lab at Harvard Medical School with lead researcher Yuancheng Lu, Life Biosciences’ epigenetic restoration program, the National Eye Institute, Altos Labs, Retro Biosciences, Turn Biotechnologies, NewLimit, Rejuvenate Bio, and the broader cellular rejuvenation, epigenetic reprogramming, and retinal-ganglion-cell restoration field.
Visual Relearning & Neural Reconnection Emerging · noninvasive
Demonstrated components (today): restored and regrown cells must wire into the visual pathway, and the brain must re-learn to read the signal — a capacity the brain already has. Perceptual-learning and visual-rehabilitation studies show adults can recover usable sight as the visual system relearns, entirely noninvasively.
The capability being built toward: bringing function back without cutting, implanting, or injecting — helping the eye-brain system re-wire and re-learn to see once cells are restored. When fully built, the aim is reliable relearning that turns a restored signal into real sight; the brain’s relearning capacity is demonstrated, and pairing it with regeneration is the emerging direction. Shared with neuroregeneration.
Noninvasive functional recovery, synaptic integration of new and regrown cells, visual-pathway reconnection, retinotopic targeting, and cortical plasticity and visual re-learning — the brain’s own ability to adapt to and use restored input. An active and essential frontier.
The brain re-learns to see. Work led by Pawan Sinha at MIT (Project Prakash) showed that people blind since early childhood can gain functional sight years later, with the visual brain gradually learning to interpret the new input — direct proof that the visual system stays plastic and can adapt to restored signals long after sight was lost.
Restored cells can wire in. Research on photoreceptor integration by Robin Ali and Rachael Pearson at University College London showed that healthy photoreceptors placed into a damaged retina can connect with the surviving circuitry and contribute to visual signaling, and lab-grown photoreceptors have been shown to reach out and form new synaptic connections — evidence that restored and regrown cells can reconnect to the pathway that carries sight to the brain.
Reconnect the signal to the brain. Restored and regrown cells still have to wire into the visual pathway, and the brain has to re-learn to use the signal — an essential frontier that decides whether regained cells become usable sight, and an active focus of vision-rehabilitation and visual-neuroscience research.
Research & institutions: the National Eye Institute, Harvard Medical School, Mass Eye and Ear, Johns Hopkins Wilmer Eye Institute, University of Minnesota vision-rehabilitation research, University of Rochester vision-science research, University of California vision-science programs, low-vision rehabilitation researchers, neuroplasticity researchers, visual-neuroscience researchers, military vision-rehabilitation research programs, Department of Defense–supported visual rehabilitation initiatives, and the broader vision-restoration and cortical-plasticity field.
Rebuild the eye’s surface with the body’s own cells Approved in Europe (human)
Demonstrated components (today): when the eye’s surface is destroyed — for example by a chemical burn — it can be rebuilt from the patient’s own limbal stem cells. Holoclar, which expands those cells to restore the corneal surface, became the first stem-cell medicine approved in Europe (2015) — own-cell restoration, demonstrated in people.
The capability being built toward: restoring the eye’s surface using nothing but the body’s own cells. Today this needs a biopsy and a surgical graft; the aim is the same own-cell restoration without surgery. When fully built, the surface is rebuilt noninvasively; the own-cell biology is approved and real, and the harm-free delivery is the direction. Linked to corneal regeneration.
Autologous limbal stem-cell expansion, corneal-surface reconstruction, and ocular-surface regeneration from the patient’s own cells — the most clinically mature route on this page.
Sight restored in people with their own stem cells. Graziella Pellegrini and Michele De Luca at the University of Modena and Reggio Emilia restored sight to patients blinded by chemical burns using the patients’ own cultured limbal stem cells to rebuild the corneal surface — reported in 112 patients in the New England Journal of Medicine (2010) and approved in Europe as Holoclar in 2015, the first stem-cell medicine approved in the Western world.
Proven to last for decades. Pellegrini and De Luca’s long-term follow-up of their own treated patients found restored, stable corneal surfaces holding for well over ten years — evidence that the body’s own cells can rebuild tissue durably, not just temporarily.
A template for own-cell restoration. Holoclar — the De Luca and Pellegrini team’s own-cell graft — established the manufacturing and regulatory path for growing a patient’s own stem cells into a living graft, the working blueprint researchers are now following to rebuild other tissues of the eye from a person’s own cells.
Research & institutions: Graziella Pellegrini and Michele De Luca at the University of Modena and Reggio Emilia and Holostem Terapie Avanzate, Ula Jurkunas and the cornea service at Mass Eye and Ear and Harvard Medical School (the CALEC cultivated autologous limbal epithelial cell trial), Virender Sangwan at the LV Prasad Eye Institute (simple limbal epithelial transplantation), Sajjad Ahmad at Moorfields Eye Hospital and University College London, Ali Djalilian at the University of Illinois Chicago, Friedrich Kruse’s ocular-surface group at the University of Erlangen, Bascom Palmer Eye Institute, the Centre for Eye Research Australia, the National Eye Institute, military-funded regenerative-medicine research initiatives relevant to vision restoration, and the broader autologous limbal stem-cell and corneal-surface restoration field.
Rebuild lost light-sensing cells Frontier · lab-stage
Demonstrated components (today): when photoreceptors are lost to degeneration, new ones can be grown from the body’s own cells — human stem cells have been grown into light-sensing retinal tissue in the lab as a potential replacement source for the cells the eye has lost.
The capability being built toward: regrowing the eye’s lost light-sensing cells and integrating them so they restore vision. When fully built, the aim is to replace lost photoreceptors and deliver them without an invasive procedure; lab-grown retinal tissue is demonstrated at the bench, and safe delivery and integration in people is the frontier.
Human pluripotent stem-cell–derived retinal organoids, photoreceptor differentiation, light-responsive cone and rod generation, and synapse-forming replacement tissue — a lab-stage replacement-cell source.
Working retinas grown from human cells. David Gamm’s lab at the University of Wisconsin–Madison grew 3D “mini-retinas” from human stem cells containing photoreceptors that respond to light like real cones and reach out to form new synaptic connections — a potential replacement-cell source for restoring lost vision (Cell Stem Cell, 2022; PNAS, 2023).
Lab-grown cells that wire themselves up. Gamm’s team showed the organoid photoreceptors don’t just sense light — they extend connections and form synapses with neighboring neurons, the step that lets a replacement cell actually pass a signal toward the brain.
From the dish toward patients. Groups worldwide — RIKEN in Japan, UCL and Moorfields in the UK, and the National Eye Institute — are advancing stem-cell-derived retinal cells toward the clinic, with the first early human studies of retinal cell therapy already underway.
Research & institutions: David Gamm’s lab at the University of Wisconsin–Madison, Robin Ali’s retinal cell-therapy research, University College London, Moorfields Eye Hospital, Kapil Bharti at the National Eye Institute, Masayo Takahashi at RIKEN, BlueRock Therapeutics, jCyte, Lineage Cell Therapeutics, Opsis Therapeutics, the Foundation Fighting Blindness, and the broader retinal-organoid and photoreceptor-replacement field.
Vision Restoration is not a single invention. It is the integration of regenerative biology, institutions, research programs, healthcare systems, and public policy into one restoration capability.
Making this real means accelerating regenerative-medicine research, supporting the careful move from animal studies to safe human trials, expanding access to the restoration capabilities already proven in people, ensuring the body’s-own-repair path leads, and making sure that when sight can be restored, it becomes available to everyone rather than a small number of people.
The goal is simple: bring back vision that was lost, reconnect people to the world, reduce disability and suffering, and restore independence and opportunity across the country.
Vote Michael Floyd for President 2028.
The honest boundary: today’s most direct ways to deliver regeneration are often invasive or carry side effects — devices, intravitreal and subretinal injections, gene delivery, cell transplantation, surgery, and drugs with known side effects. These may be important areas of medical research, but under Michael Floyd’s Healthy standard they do not count as finished solutions and are not the preferred model — they qualify only when future versions become noninvasive, precisely controlled, durable, safe, and free of treatment-related harm. Much of the strongest restoration evidence is still in animal models, regrown connections are often partial, and restored cells must still wire correctly to the brain. So the real challenges are leading with the body’s own repair, proving regeneration safe and durable in people, and integrating the fragmented pieces — with restoration working alongside preservation across a whole life of sight.
Picture the day this is routine. A diagnosis of vision loss no longer reads as a sentence — it reads as the start of a plan. People come to expect that sight can be helped to heal, because restoration leads with the body’s own repair instead of asking patients to simply adapt to the dark.
Families stop reorganizing their lives around a loved one’s lost sight. A grandparent sees a grandchild’s face for the first time. A parent reads to a child again. The quiet, daily losses that ripple out from one person’s blindness — the rides given up, the work handed off, the independence surrendered — begin to reverse.
Society gets back what blindness takes away. Millions return to driving, to reading, to working, to full participation — and the enormous human and economic weight of vision loss, carried today by patients, caregivers, and the country alike, starts to lift.
Eye care shifts from managing decline to restoring function — this is Michael Floyd’s Healthy standard applied to the eye, the same standard that works to prevent, regenerate, restore, and optimize health across the entire body, all by the body’s own repair. The goal has never wavered: the body’s own cells, doing the body’s own work, without new harm.
And America becomes a country that decides lost sight should be brought back — and helps turn a worldwide scientific effort into care its people can actually receive, by the body’s own repair and without new harm.
Help Build Vision Restoration
No person should be told that their blindness is permanent when the science to bring sight back is already emerging. No family should accept that a loved one will never see their face again. No one should lose the world when the body’s own power to repair the eye can be reawakened.
This future will not build itself.
It requires researchers, engineers, healthcare professionals, patients, families, supporters, volunteers, organizers, donors, and citizens working together to make regenerative, restoration-first healthcare available to everyone. If you believe lost sight should be brought back, join the movement helping build that future.
Help build Free Safe Healthy.